BAX.GQ Bond Profile: Coupon and Redemption
This article provides a detailed profile of the BAX.GQ bond issued by Baxter International Inc., highlighting its key facts such as issuer, issue and maturity dates, face value, and minimum denomination. It also outlines the bond's coupon payment schedule, featuring a fixed rate of 6.25% paid semi-annually, and redemption information including the outstanding amount. The profile offers an in-depth breakdown for evaluating the bond's potential and performance.
Baxter International stock after-hours at EUR 20.82: minus 0.95 percent versus prior close
Baxter International stock closed after-hours at EUR 20.82, showing a 0.95 percent decrease from its prior close. The company also released its 2026 Connected Hospital Report, highlighting technology investments as essential for future growth among surveyed hospitals, although most believe they are not maximizing their impact. The report identifies operational efficiency, workflow automation, and data integration as key priorities, with varying adoption rates across different hospital technology maturity levels.
Baxter International stock: Company releases Connected Hospital Report on September 30, 2026
Baxter International Inc. announced the release of its 2026 Connected Hospital Report on September 30, 2026. The report, based on a survey of 150 IT and nursing leaders, examines how U.S. hospitals are leveraging technology investments to improve clinical and operational outcomes. It highlights the importance of strong integration among IT systems, medical devices, and software applications for future innovation.
Baxter International stock faces a Q3 EPS estimate cut
Baxter International (BAX) is facing a Q3 2026 EPS estimate cut from $0.53 to $0.51, according to MarketBeat and Zacks Research, which maintains a Hold rating. Despite a strong Q2 performance with EPS of $0.56 and revenue of $2.96 billion, the lowered Q3 estimate and the company's full-year EPS guidance of $1.95-2.15 suggest tempered near-term expectations. The company's market capitalization stands at $12.1 billion with its next earnings report due on October 29, 2026.
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger.
AngioDynamics CEO James C. Clemmer announced his intention to retire by November 30, 2026, or upon the appointment of a successor, with the possibility of monthly extensions by mutual agreement. The company recently amended its fiscal 2026 annual report to include updated XBRL tagging and disclosed performance against cash-incentive targets, showing net sales of $320.2 million against a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. Executive compensation for fiscal 2026 was largely performance-based, with cash incentive payouts at 180% of target for named executive officers.
Tariff Cuts Put NovoCure Stock And Medical Exporters Back In Focus
Recent tariff cuts between the US and China are re-opening trade channels, specifically benefiting agricultural and medical exporters. This article highlights three US-listed stocks—SWS Hemodialysis Care (SHSE:688410), APT Medical (SHSE:688617), and NovoCure (NVCR)—that are poised to benefit from these policy changes. It encourages investors to examine these and other related companies to assess their altered risk and reward profiles.
Baxter International stock trades above analyst target
Baxter International Inc. (BAX) closed at USD 23.49 on September 28, 2026, exceeding the USD 22.45 consensus analyst target. The company reported a 5% increase in Q2 revenue to USD 2.96 billion and raised its 2026 sales growth and adjusted EPS guidance. Despite this positive performance, profitability remains a challenge, with adjusted gross and operating margins declining in Q2.
What Is Drawing Attention To Axogen (AXGN)?
Axogen (AXGN) has garnered attention due to recent share price movements, showing a decline over the past month and three months but significant gains over the last year. Despite the recent pullback, which has brought its price to approximately 11% below an estimated intrinsic value and 25% below the average analyst target, the company's valuation narrative suggests it is 19% undervalued at $53.22. However, the article also notes potential risks due to Axogen's reliance on its Avance Nerve Graft and a high P/S ratio compared to industry peers.
Healthcare Equipment and Supplies Stocks Q2 Highlights: GE HealthCare (NASDAQ:GEHC)
This article reviews the Q2 performance of several healthcare equipment and supplies stocks, highlighting GE HealthCare (GEHC), Baxter (BAX), LeMaitre (LMAT), STERIS (STE), and Lantheus (LNTH). It details their revenue performance against analyst expectations and stock price movements, noting GE HealthCare's satisfactory quarter with increased orders, Baxter's strong revenue beat, LeMaitre's disappointing results and guidance, STERIS's mixed quarter, and Lantheus's impressive revenue and EPS beat. The sector as a whole saw a decline in share prices despite revenues generally beating estimates.
Baxter International (BAX) Q1 2026 Earnings Call Transcript
This article provides the transcript of Baxter International's Q1 2026 Earnings Call, held on April 30, 2026, at 8:30 AM EDT. The call featured key company participants including the VP of Investor Relations, President and CEO, and Interim CFO, along with questions from various analysts. It details the company's financial performance and discussions during the quarterly earnings report.
Baxter International stock heads into the open after a 1.9 percent S&P 500 drop
Baxter International stock is opening after the S&P 500 experienced a 1.9% drop. On September 23, 2026, Baxter International closed at USD 23.49 on the New York Stock Exchange. The S&P 500 closed at 7,704.13 on September 24, 2026, showing a slight decline amid pressure from high yields.
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
Baxter International (BAX) is undergoing a portfolio transformation, focusing on operational efficiency, connected-care growth, and strengthening high-growth businesses. While the company faces challenges like margin pressure from manufacturing costs, tariffs, and regulatory issues with Novum IQ, its large addressable markets and portfolio simplification initiatives support its long-term growth outlook. Shares of the Zacks Rank #3 (Hold) company have gained 23% year to date, outperforming the industry and the S&P 500 Index.
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
Baxter International (BAX) is undergoing a portfolio transformation, focusing on operational efficiency and growth in connected-care and advanced surgery businesses. While facing headwinds from manufacturing costs, tariffs, and regulatory issues with Novum IQ, the company benefits from large addressable markets and strategic simplification. Analysts project revenue growth for 2026 but a decrease in adjusted EPS, despite recent positive revisions.
Baxter International stock heads into the open after a 1.2 percent drop
Baxter International stock experienced a 1.2 percent drop on September 23, 2026, closing at USD 30.18, amidst a broader S&P 500 decline of 0.8 percent, pressured by rising Treasury yields. Investors are looking to the company's next reporting date on October 29, 2026, for specific news. The broader market trend of increased Treasury yields and elevated oil prices continues to influence US equities.
Intuitive Surgical, Inc. (ISRG) Options Chain - Yahoo Finance
This article provides the options chain for Intuitive Surgical, Inc. (ISRG) on Yahoo Finance. It indicates that there are currently no calls or puts available, with options data delayed by 15 minutes. The page also displays current stock information for ISRG, showing a price of 396.65 with a -1.35% change as of 1:49:36 p.m. EDT.
Baxter International stock holds at USD 22.93 as storm damage weighs
Baxter International's stock is holding at USD 22.93, with its outlook weakened due to storm damage at its North Carolina manufacturing hub. This damage has caused supply chain disruptions, margin pressure, and reduced earnings guidance, keeping the stock near the lower end of its 52-week range. The company's immediate challenge is to restore output and contain remediation costs.
Baxter International stock holds near its yearly high
Baxter International stock closed at USD 22.93 on September 21, 2026, after gaining 14.6 percent in three months, though it remains 23.57 percent below its 52-week high. Analysts have set a consensus "Hold" rating with a mean target price of USD 27.00, indicating a potential 17.75 percent upside from its current price. The company's market capitalization stands at USD 11.79 billion.
Baxter International, McDowell County
The article briefly mentions that Baxter International's North Cove facility, located near Marion, NC, is a significant producer of bagged IV fluids for the United States. It was published by the Asheville Citizen-Times.
Otsuka ICU Medical Recalls One Lot of IV Saline After Potassium Chloride Bag Found Inside Saline Overwrap
Otsuka ICU Medical LLC has issued a recall for one lot of 0.9% Sodium Chloride Injection, USP (saline) after a customer discovered a bag of concentrated potassium chloride inside a saline-labeled overwrap. The recall, affecting lot 1042188, targets hospitals and clinics, though no adverse events have been reported. The primary safeguard against accidental administration is the clear labeling on the inner potassium chloride bag, requiring healthcare professionals to check before use.
11 Tractor Supply Tools Under $50 Worth Adding To Your Collection
This article highlights 11 useful tools available at Tractor Supply Co. for under $50, emphasizing that good quality tools can be found at affordable prices. It details various tools from brands like DeWalt, Crescent, Skil, GearWrench, Fiskars, Arrow, Black+Decker, and Apollo Tools, explaining their features and practical applications for homeowners and DIY enthusiasts. The selections aim to provide versatility and value, proving that expanding a toolkit doesn't require a large investment.
US FDA Warning To Bausch + Lomb Suggests Potential For Recall, Production Interruption
The US FDA has issued a warning to Bausch + Lomb, indicating a potential recall and production interruption for the company. This warning suggests that a recall would be necessary if the firm's response to the FDA's concerns is not deemed satisfactory. The article highlights the implications for Bausch + Lomb's ophthalmic supply chain and manufacturing operations.
Alkermes appoints Anne Whitaker to board of directors
Alkermes plc announced the appointment of Anne C. Whitaker as an independent director to its board. Whitaker brings extensive experience from leadership roles at various biopharmaceutical companies, including CEO positions at Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals Corporation. She also serves on the boards of several publicly-traded and private companies and holds a B.S. in chemistry.
LMRI - Lumexa Imaging Holdings Inc Volatility & Greeks
This article provides a detailed financial overview of Lumexa Imaging Holdings Inc (LMRI), including its latest stock price, market capitalization, key financial ratios, earnings per share, and institutional/insider ownership. It also presents volatility metrics, price performance over various periods, and analyst recommendations. The data highlights various financial health indicators and market sentiment for the company.
Baxter International stock extends its 2026 gains
Baxter International stock closed at USD 23.80 on September 11, 2026, marking a 24.5 percent gain from the start of the year. Despite this performance, analysts maintain a cautious "Hold" rating with an average price target of USD 22.45, which the current stock price exceeds. The company reported strong Q2 2026 earnings, beating estimates, and provided positive FY 2026 guidance, though the stock remains near its 52-week high but below the top of its range.
Baxter International Inc. (BAX) Stock Analysis: Exploring The 20.7% Upside Potential
Baxter International Inc. (BAX) currently trades at $23.80, with analysts projecting a 20.7% upside potential, targeting $28.73. Despite negative EPS and ROE, the company shows a 5.3% revenue growth and over $1 billion in free cash flow, suggesting financial resilience. Analyst sentiment is cautiously optimistic with a majority hold rating, highlighting both growth opportunities and profitability challenges.
Baxter: This Turnaround Stock Is Up and Still 38% Undervalued
Baxter International's stock is experiencing a turnaround in 2026, driven by new management's successful plans after years of underperformance. Despite potential volatility, Morningstar believes the stock is 38% undervalued with a fair value estimate of $40, rating it as a compelling turnaround play. The company, a top-tier medical supplier, is expected to see profit growth due to easing supply chain pressures and new contracts, with an 8% annual EPS growth forecast through 2030.
MiniMed Group (MMED) Stock Forecast and Price Target 2026
This article provides a stock forecast and price target for MiniMed Group (MMED) for 2026, based on analysis from 16 Wall Street analysts. The consensus rating is "Moderate Buy" with an average price target of $23.77, representing a potential upside of 5.64% from its current price. Recent analyst actions show several boosts to price targets, reflecting a generally positive outlook.
Transcript : Baxter International Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 12
This article provides a transcript of Baxter International Inc.'s presentation at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, at 12:45 PM EDT. The event included a speech by Larry Biegelsen, the medical device analyst at Wells Fargo. The full transcript is available to subscribers of MarketScreener.
Baxter International Inc. stock underperforms Wednesday when compared to competitors
Baxter International Inc. (BAX) stock fell by 1.89% to $24.39 on Wednesday, underperforming the broader market. This decline occurred during a generally poor trading session where the S&P 500 Index dropped 0.48% and the Dow Jones Industrial Average fell 0.77%. This marks the second consecutive day of losses for Baxter's stock.
Baxter International stock trades sideways as technical signals flag limited near-term upside
Baxter International stock is currently trading in the mid-$20s range, with technical analysis suggesting limited near-term upside and potential for modest downside. The stock is exhibiting a narrow risk-reward profile, oscillating within tight support and resistance levels. The company's business model, anchored in hospital and renal therapies, provides a foundation for its long-term earnings capacity, despite short-term technical patterns.
Baxter International Inc. stock underperforms Tuesday when compared to competitors
Baxter International Inc. (BAX) stock fell 3.76% to $24.86 on Tuesday, underperforming the broader market. The S&P 500 Index declined by 0.58% and the Dow Jones Industrial Average dropped by 1.18%. The company's stock is currently 17.13% below its 52-week high of $30.00.
CooperCompanies (COO) To Report Earnings Tomorrow: Here Is What To Expect
CooperCompanies (COO) is set to report its earnings after market close on Wednesday. Analysts expect revenue to grow 3.5% year-over-year, a slowdown from the previous year's 5.7% increase. While some peers in the medical devices and supplies segment have beaten expectations, CooperCompanies' stock is down 8.4% over the last month, heading into earnings below its average analyst price target.
Don't Ignore The Insider Selling In Abeona Therapeutics
An independent director at Abeona Therapeutics recently sold US$88k worth of stock, reducing their holding by 19%. This follows a larger sale by the President in the last year. While insiders haven't been buying, the company's insiders still own 16% of the company, valued at US$55 million.
ETFs Investing in Baxter International Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Baxter International Inc. The funds are sorted by market value and provide key statistics such as issuer, management style, expense ratio, AUM, price, change percentage, and 3-year NAV total return. The information aims to assist investors in identifying ETFs with exposure to Baxter International Inc.
Baxter International stock holds steady as investors focus on recent restructuring and earnings prof
Baxter International's stock is stable as investors evaluate its latest earnings, restructuring efforts, and the spin-off of its kidney care business. The company's focus on improving operating margins, streamlining operations, and strengthening its balance sheet post-spin-off is attracting investor attention. These strategic moves aim to enhance long-term return on invested capital and maintain financial health in a competitive market.
Baxter International Inc. stock underperforms Friday when compared to competitors despite daily gains
Baxter International Inc. (BAX) shares rose 1.02% on Friday, closing at $25.83, despite a general market downturn. The S&P 500 Index and Dow Jones Industrial Average both fell. The stock is currently 13.90% below its 52-week high of $30.00, reached on July 30th.
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's dividend continues to grow despite the significant decline in Humira sales, thanks to substantial free cash flow. The company is relying on newer drugs like Skyrizi and Rinvoq to offset Humira's lost revenue, but Skyrizi faces its own patent expiration in 2033. While the recent Apogee acquisition adds leverage and dilutes EPS, management aims to reduce net leverage within three years.
Baxter International CEO Andrew P. Hider Surrenders Shares for Tax Withholding on September 2, 2026
Andrew P. Hider, President and CEO of Baxter International Inc., forfeited 54,276 shares of common stock on September 2, 2026, for tax withholding purposes related to vested restricted stock units. The shares were valued at $25.70 each, and after the transaction, Hider directly retained 518,447 shares. This transaction was officially reported on September 3, 2026.
Baxter International's Julie Foster Reports RSU-Related Share Forfeiture
Julie Foster, President of Front Line Care at Baxter International Inc., reported a share forfeiture on September 2, 2026. This transaction involved 2,098 shares of Common Stock, valued at $25.7 per share, forfeited to cover tax withholding obligations from vested restricted stock units. After the forfeiture, Foster directly held 29,164 shares of Common Stock.
ICUI: ICU Medical, Inc. Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of ICU Medical, Inc. (ICUI), including its current stock price ($161.60), market capitalization ($3.88B), and key financial metrics. It highlights the company's focus on innovative medical products for infusion therapy and critical care, and mentions recent news such as CFO stock sales and an analyst's market sentiment. The company was founded in 1984 and is headquartered in San Clemente, CA.
Baxter (NYSE: BAX) exec ends with 29,164 shares after tax move
Baxter International executive Julie Foster had 2,098 shares withheld to cover tax obligations related to the vesting of restricted stock units (RSUs) on September 2, 2026. These RSUs were granted on September 2, 2025, at a reference price of $25.70 per share. Following this transaction, Foster directly holds 29,164 shares of Baxter common stock, which includes reinvested dividends.
ShinyHunters Claims Theft of 284M Records from Healthcare Giant McKesson
The healthcare giant McKesson recently disclosed a cyberattack in an SEC filing, confirming data exfiltration although the full extent is still under investigation. The ShinyHunters extortion group has claimed responsibility, alleging the theft of 284 million patient data records, including sensitive information like Social Security numbers and medical data, from McKesson's systems. The incident, detected on August 25, 2026, primarily impacted customers of its Oncology & Multispecialty and Medical-Surgical business units, with McKesson working to minimize impact and determine materiality.
News - ShinyHunters claims theft of more than 7.1 million Baxter International records
Medical technology firm Baxter International has disclosed a major cybersecurity incident after the ShinyHunters hacking group claimed to have infiltrated its systems and exfiltrated over 7.1 million records. The company launched an investigation with external experts and informed law enforcement, stating that there has been no impact on its manufacturing operations, customer services, or business continuity. The ShinyHunters group released the stolen data on August 19th after unsuccessful ransom negotiations.
McKesson investigating cybersecurity incident involving 'exfiltration of certain data'
McKesson is investigating a cybersecurity incident that involved "unauthorized access to certain third-party applications and the exfiltration of certain data" from its Oncology & Multispecialty and Medical-Surgical business units. The hacker group ShinyHunters claims responsibility, stating they used voice-phishing to steal 284 million patient records and are demanding a $55 million ransom. This incident follows similar attacks on other major healthcare companies by ShinyHunters.
Saline bags recalled in 14 states due to potential fiberglass contamination
Saline bags have been recalled in 14 states due to potential contamination with fiberglass. The recall is a precautionary measure to ensure patient safety and prevent any adverse health effects from the contaminated products. Consumers in the affected states should check their saline bags and follow recall instructions.
Fiberglass in IV saline? Texas among states included in recall
Baxter International Inc. has issued a recall for two lots of its 0.9% Sodium Chloride Injection due to potential fiberglass contamination. The FDA warns that intravenous administration of solutions containing fiberglass could lead to serious health consequences, including blood clots, organ damage, or death, though no adverse effects have been reported yet. The affected products were distributed to healthcare providers in over a dozen states, including Texas, between July 31 and August 3, 2026.
Saline bags recalled in 14 states due to potential fiberglass contamination
Baxter International Inc. has issued a recall for two lots of 0.9% Sodium Chloride Injection saline bags across 14 states due to potential fiberglass contamination. The presence of fiberglass could lead to severe health issues, including blood clots or death, although no injuries have been reported yet. The recalled bags, identified by lot numbers Y495523 and Y495523A, were distributed between July 31 and August 3 to healthcare facilities in states including Florida, Illinois, and Texas.
Baxter Recalls Three Intravenous Solutions on the Same Day Over Fiberglass and Stainless Steel Particle Concerns
Baxter International has announced three separate nationwide recalls of intravenous solutions due to potential contamination with foreign particles, specifically fiberglass and stainless steel. While no adverse events have been reported yet, the recalls are considered serious due to the risk of particles blocking blood vessels, causing blood clots, or leading to organ damage or death. Patients receiving home parenteral nutrition in Alabama, Georgia, or Tennessee are advised to contact their compounding pharmacy if they used the recalled dextrose lot.
Gartner Research: Healthcare Supply Chain Leaders Must Transition to Self-Managing AI Inventory Rooms
Gartner advises healthcare Chief Supply Chain Officers (CSCOs) to replace manual inventory counting with autonomous supply rooms utilizing computer vision and artificial intelligence. These AI-driven rooms autonomously monitor inventory, predict demand, and trigger reorders, freeing up clinical staff from manual tasks. Gartner emphasizes evaluating new technologies based on their ability to eliminate physical labor rather than just speeding it up, allowing nurses more time with patients.
IV Saline Recalled Nationwide Over Possible Fiberglass Contamination, FDA Says
Baxter International Inc. has issued a nationwide recall for two lots of its 0.9% sodium chloride injection due to potential fiberglass contamination. The FDA announced that continued use of the affected product could lead to serious health issues such as blood vessel blockage, pulmonary embolism, organ damage, or death. While no health issues have been reported yet, customers are advised to discontinue use and return the product.
